Please assess the completion status of the following clinical trial:

Trial Title: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:-~* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.~* Male or female, age 18 years or older at the time of signing informed consent.~* Type 2 diabetes mellitus diagnosis.~* Treatment with either 1 or 2 oral antidiabetic medications.~* Current member of a commercial or Medicare health plan with pharmacy benefits.~* Recorded HbAlc value within the last 90 days prior to randomization.~* Further intensification with an additional antidiabetic oral or injectable medication is indicated to achieve glycemic target at the discretion of the study physician according to approved labelling.~Exclusion Criteria:~* Previous randomization in this study~* Treatment with more than 2 oral antidiabetic medications, oral semaglutide, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of any type of insulin is allowed, as is prior insulin treatment for gestational diabetes.~* Contraindications to semaglutide according to the Food and Drug Administration approved label.~* Female who is pregnant, breastfeeding or intends to become pregnant~* Participation in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive semaglutide subcutaneously (s.c.) in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.
- Standard of care (Type: ACTIVE_COMPARATOR): Participants will receive standard of care in addition to metformin monotherapy as treatment intensification in the course of routine clinical practice. Participants will be followed for 2 years, regardless of changes in antidiabetic treatment over the course of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).